Posts Tagged: R&D
Everything Depends on Coronavirus R&D Partnerships—Don’t Let the Critics Wreck Them
The world is teetering on the brink of a public health and economic catastrophe, depending on emergency partnerships between our public and private sectors to develop a …
Identifying the Crucial Qualities of Great IP Managers
IPWatchdog readers know the importance of capturing IP, whether it is patents, trademarks, copyrights, or trade secrets. This article isn’t detailing technical tips for filing patents …
Severing the Link Between IP and Biomedical Innovation Isn’t the Answer to Global Health Care Challenges
The cost of medicines is on the agenda this week at the World Health Organization’s annual executive board meeting in Geneva. Nongovernmental organizations and certain middle-income …
From Research to Market Value: Innovation Value Teams
In a recent article in Harvard Business Review, "Real Innovation Requires More Than an R&D Budget,” Dr. Gina O’Connor makes the case for having three …
Three Key Strategies for Adapting Patent Departments to Agile Innovation Settings
As companies grow their digital business, many R&D organizations transition to Agile innovation practices*, both in software and hardware development. Any implementation of Agile leads to …
Links to China Prompt Purge at Moffitt Cancer Center
Underscoring the seriousness of the threat posed by the Chinese government's campaign to obtain results of U.S. publicly funded research, the Board of Directors at the …
Don’t Undermine U.S. Innovation While Standing Up to China
One of the few areas of bipartisan agreement in Washington is that it's time to respond to Chinese economic and military aggression. The need is underscored by …
WIPO Report—Innovation Is Increasingly Collaborative and International
Innovative activity is more collaborative and transnational, but also focused on a few large clusters in a few countries. These are among the findings in the latest …
Will Bayh-Dole Survive Its 40th Birthday?
Next year marks the 40th anniversary of the passage of the Bayh-Dole Act. With election day looming, 2020 is likely to be the most politically contentious year of …
Don’t Ignore the Flashing Caution Lights in the Drug Pricing Debate
Trying to rationally address hot button issues in an election year is always a dangerous proposition. That's particularly true as we approach what promises to be one …
The ‘Dragon’ Targets U.S. Biopharma Lead
Perhaps the report on China's strategy for eclipsing the U.S. lead in biopharma from the Information Technology & Innovation Foundation (ITIF) resonated so strongly with me because …
Bayh-Dole Rocks While the Critics Play the Same False Note
A just-released study co-sponsored by the Biotechnology Innovation Organization (BIO) and AUTM provides new evidence of the significant contribution academic patent licensing makes to the U.S. …
Restoring IP Rights After the Destructive, Unjust Antitrust Rendering in FTC v. Qualcomm
If a judge ever botched an antitrust case involving patents, the prize may go to federal district Judge Lucy Koh for her ruling in favor of the …
The Price of Price Controls: Innovation Likely to Suffer in Drug Pricing Debate
Is Congress really going to do anything useful with respect to lowering drug prices? When the question is presented that way the answer almost seems painfully obvious. …
Patent Trends Study Part Six: Medical Devices Industry
In the sixth installment of our 13-part patent-trends study (performed in collaboration with GreyB) providing high-level data across industries, we will examine trends in the medical-device industry. …
